{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:42:55Z","timestamp":1789764175504,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ceroid lipofuscinoses neuronal 6 (CLN6) disease belongs to the neuronal ceroid lipofuscinoses (NCLs), complex and genetically heterogeneous disorders with wide geographical and phenotypic variation. The first clinical signs usually appear between 18\u00a0months and 8 years, but examples of later-onset have also been reported. Common manifestations include ataxia, seizures, vision impairment, and developmental regression. Because these are shared by other neurological diseases, identification of <jats:italic>CLN6<\/jats:italic> genetic variants is imperative for early diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We present one of the largest cohorts to date of genetically diagnosed CLN6 patients screened at a single center. In total 97 subjects, originating from 20 countries were screened between 2010 and 2020. They comprised 86 late-infantile, eight juvenile, and three adult-onset cases (two patients with Kufs disease type A, and one with teenage progressive myoclonic epilepsy). The male to female ratio was 1.06: 1.00. The age at referral was between six months and 33\u00a0years. The time from disease onset to referral ranged from less than 1 month to 8.3\u00a0years. The clinical phenotype consisted of a combination of symptoms, as reported before.\u00a0We characterized a total of 45 distinct variants defining 45 distinct genotypes. Twenty-four were novel variants, some with distinct geographic associations. Remarkably, c.257A\u2009&gt;\u2009G (p.H86R) was present in five out of 23 unrelated Egyptian individuals but in no patients from other countries. The most common genotype was homozygosity for the c.794_796del in-frame deletion. It was present in about one-third of CLN6 patients (28 unrelated cases, and 2 familial cases), all with late-infantile onset. Variants with a high likelihood of causing loss of CLN6 function were found in 21% of cases and made up 33% of all distinct variants. Forty-four percent of variants were classified as pathogenic or likely pathogenic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study significantly expands the number of published clinical cases and the mutational spectrum of disease-associated <jats:italic>CLN6<\/jats:italic> variants, especially for the Middle Eastern and North African regions. We confirm previous observations regarding the most prevalent symptoms and recommend including <jats:italic>CLN6<\/jats:italic> in the genetic diagnosis of patients presenting with early-onset abnormalities of the nervous system, musculoskeletal system, and eye.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02288-8","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:03:12Z","timestamp":1651579392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical and genetic characterization of a cohort of 97 CLN6 patients tested at a single center"],"prefix":"10.1186","volume":"17","author":[{"given":"Corina-Marcela","family":"Rus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weissensteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Susnea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bright D.","family":"Danquah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Morales Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Saravanakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanth","family":"Mannepalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna K.","family":"Kandaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Di Bucchianico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Rolfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-2895","authenticated-orcid":false,"given":"Christian","family":"Beetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"issue":"4","key":"2288_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1542\/peds.44.4.570","volume":"44","author":"W Zeman","year":"1969","unstructured":"Zeman W, Dyken P. Neuronal ceroid-lipofuscinosis (Batten\u2019s disease): relationship to amaurotic family idiocy? Pediatrics. 1969;44(4):570\u201383.","journal-title":"Pediatrics"},{"issue":"3","key":"2288_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","volume":"6","author":"SE Mole","year":"2005","unstructured":"Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics. 2005;6(3):107\u201326.","journal-title":"Neurogenetics"},{"issue":"6","key":"2288_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1177\/088307389501000602","volume":"10","author":"HH Goebel","year":"1995","unstructured":"Goebel HH. The neuronal ceroid-lipofuscinoses. J Child Neurol. 1995;10(6):424\u201337.","journal-title":"J Child Neurol"},{"issue":"10","key":"2288_CR4","first-page":"850","volume":"1762","author":"M Haltia","year":"2006","unstructured":"Haltia M. The neuronal ceroid-lipofuscinoses: from past to present. Biochem Biophys Acta. 2006;1762(10):850\u20136.","journal-title":"Biochem Biophys Acta"},{"issue":"2","key":"2288_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","volume":"79","author":"RE Williams","year":"2012","unstructured":"Williams RE, Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79(2):183\u201391.","journal-title":"Neurology"},{"issue":"1","key":"2288_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1055\/s-2007-973654","volume":"28","author":"P Uvebrant","year":"1997","unstructured":"Uvebrant P, Hagberg B. Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures. Neuropediatrics. 1997;28(1):6\u20138.","journal-title":"Neuropediatrics"},{"issue":"3","key":"2288_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1399-0004.2008.01054.x","volume":"74","author":"SJ Moore","year":"2008","unstructured":"Moore SJ, Buckley DJ, MacMillan A, Marshall HD, Steele L, Ray PN, et al. The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland. Clin Genet. 2008;74(3):213\u201322.","journal-title":"Clin Genet"},{"key":"2288_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-1172-8-19","volume":"8","author":"FM Santorelli","year":"2013","unstructured":"Santorelli FM, Garavaglia B, Cardona F, Nardocci N, Bernardina BD, Sartori S, et al. Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy. Orphanet J Rare Dis. 2013;8:19.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2288_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.bbamcr.2008.11.004","volume":"1793","author":"A Jalanko","year":"2009","unstructured":"Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 2009;1793(4):697\u2013709.","journal-title":"Biochim Biophys Acta"},{"issue":"10 Pt B","key":"2288_CR10","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","volume":"1852","author":"SE Mole","year":"2015","unstructured":"Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta. 2015;1852(10 Pt B):2237\u201341.","journal-title":"Biochim Biophys Acta."},{"key":"2288_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.conb.2021.08.003","volume":"72","author":"JJ Brudvig","year":"2021","unstructured":"Brudvig JJ, Weimer JM. On the cusp of cures: breakthroughs in Batten disease research. Curr Opin Neurobiol. 2021;72:48\u201354.","journal-title":"Curr Opin Neurobiol"},{"issue":"1","key":"2288_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40478-018-0646-6","volume":"6","author":"S Beck-Wodl","year":"2018","unstructured":"Beck-Wodl S, Harzer K, Sturm M, Buchert R, Riess O, Mennel HD, et al. Homozygous TBC1 domain-containing kinase (TBCK) mutation causes a novel lysosomal storage disease\u2014a new type of neuronal ceroid lipofuscinosis (CLN15)? Acta Neuropathol Commun. 2018;6(1):145.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2288_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ajhg.2011.07.003","volume":"89","author":"L Noskova","year":"2011","unstructured":"Noskova L, Stranecky V, Hartmannova H, Pristoupilova A, Baresova V, Ivanek R, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet. 2011;89(2):241\u201352.","journal-title":"Am J Hum Genet"},{"key":"2288_CR14","doi-asserted-by":"crossref","unstructured":"Rechtzigel MJ, Meyerink BL, Leppert H, Johnson TB, Cain JT, Ferrandino G, et al. Transmembrane Batten disease proteins interact with a shared network of vesicle sorting proteins to regulate synaptic composition and function. 2021:2021.09.16.460691.","DOI":"10.3389\/fnins.2022.834780"},{"issue":"9","key":"2288_CR15","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1002\/jnr.22032","volume":"87","author":"JW Benedict","year":"2009","unstructured":"Benedict JW, Getty AL, Wishart TM, Gillingwater TH, Pearce DA. Protein product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscinosis interacts with CRMP-2. J Neurosci Res. 2009;87(9):2157\u201366.","journal-title":"J Neurosci Res"},{"key":"2288_CR16","doi-asserted-by":"crossref","unstructured":"Koh S, Cain J, Magee H, White K, Rechtzigel M, Meyerink B, et al. A CLN6-CRMP2-KLC4 complex regulates anterograde ER-derived vesicle trafficking in cortical neurites. 2021:2021.09.16.460653.","DOI":"10.1101\/2021.09.16.460653"},{"issue":"5","key":"2288_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajhg.2011.04.004","volume":"88","author":"T Arsov","year":"2011","unstructured":"Arsov T, Smith KR, Damiano J, Franceschetti S, Canafoglia L, Bromhead CJ, et al. Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. Am J Hum Genet. 2011;88(5):566\u201373.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2288_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199704000-00005","volume":"56","author":"J Tyynela","year":"1997","unstructured":"Tyynela J, Suopanki J, Santavuori P, Baumann M, Haltia M. Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry. J Neuropathol Exp Neurol. 1997;56(4):369\u201375.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"2288_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","volume":"15","author":"TB Johnson","year":"2019","unstructured":"Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161\u201378.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"2288_CR20","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.ymthe.2019.06.015","volume":"27","author":"JT Cain","year":"2019","unstructured":"Cain JT, Likhite S, White KA, Timm DJ, Davis SS, Johnson TB, et al. Gene Therapy corrects brain and behavioral pathologies in CLN6-batten disease. Mol Ther J Am Soc Gene Ther. 2019;27(10):1836\u201347.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"2","key":"2288_CR21","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ymgme.2020.12.061","volume":"132","author":"E de los Reyes","year":"2021","unstructured":"de los Reyes E, Aylward S, Meyer K, Lehwald L, Albright C, Rogers DL, et al. Single-dose AAV9-CLN6 gene transfer slows the decline in motor and language function in variant late infantile neuronal ceroid lipofuscinosis 6: Interim results from phase 1\/2 trial. Mol Genet Metab. 2021;132(2):S32\u20133.","journal-title":"Mol Genet Metab."},{"issue":"2","key":"2288_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ymgme.2018.12.001","volume":"126","author":"JJ Chin","year":"2019","unstructured":"Chin JJ, Behnam B, Davids M, Sharma P, Zein WM, Wang C, et al. Novel mutations in CLN6 cause late-infantile neuronal ceroid lipofuscinosis without visual impairment in two unrelated patients. Mol Genet Metab. 2019;126(2):188\u201395.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2288_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/mgg3.262","volume":"5","author":"D Trujillano","year":"2017","unstructured":"Trujillano D, Oprea GE, Schmitz Y, Bertoli-Avella AM, Abou Jamra R, Rolfs A. A comprehensive global genotype-phenotype database for rare diseases. Mol Genet Genom Med. 2017;5(1):66\u201375.","journal-title":"Mol Genet Genom Med"},{"issue":"9","key":"2288_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0883073813494268","volume":"28","author":"JW Mink","year":"2013","unstructured":"Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28(9):1101\u20135.","journal-title":"J Child Neurol"},{"key":"2288_CR25","unstructured":"Team RC. R: A Language and Environment for Statistical Computing. 2021."},{"issue":"1","key":"2288_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/humu.10227","volume":"22","author":"JD Sharp","year":"2003","unstructured":"Sharp JD, Wheeler RB, Parker KA, Gardiner RM, Williams RE, Mole SE. Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. Hum Mutat. 2003;22(1):35\u201342.","journal-title":"Hum Mutat"},{"issue":"1","key":"2288_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pediatrneurol.2009.01.012","volume":"41","author":"MA Al-Muhaizea","year":"2009","unstructured":"Al-Muhaizea MA, Al-Hassnan ZN, Chedrawi A. Variant late infantile neuronal ceroid lipofuscinosis (CLN6 gene) in Saudi Arabia. Pediatr Neurol. 2009;41(1):74\u20136.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"2288_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.12998\/wjcc.v7.i2.203","volume":"7","author":"O Nafi","year":"2019","unstructured":"Nafi O, Ramadan B, Riess O, Buchert R, Froukh T. Two cases of variant late infantile ceroid lipofuscinosis in Jordan. World J Clin Cases. 2019;7(2):203\u20138.","journal-title":"World J Clin Cases"},{"issue":"2","key":"2288_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1086\/338190","volume":"70","author":"H Gao","year":"2002","unstructured":"Gao H, Boustany RM, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, et al. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet. 2002;70(2):324\u201335.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2288_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1086\/338708","volume":"70","author":"RB Wheeler","year":"2002","unstructured":"Wheeler RB, Sharp JD, Schultz RA, Joslin JM, Williams RE, Mole SE. The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am J Hum Genet. 2002;70(2):537\u201342.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2288_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s10038-019-0569-5","volume":"64","author":"T Mizuguchi","year":"2019","unstructured":"Mizuguchi T, Suzuki T, Abe C, Umemura A, Tokunaga K, Kawai Y, et al. A 12-kb structural variation in progressive myoclonic epilepsy was newly identified by long-read whole-genome sequencing. J Hum Genet. 2019;64(5):359\u201368.","journal-title":"J Hum Genet"},{"issue":"8","key":"2288_CR32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41436-021-01159-0","volume":"23","author":"AM Bertoli-Avella","year":"2021","unstructured":"Bertoli-Avella AM, Kandaswamy KK, Khan S, Ordonez-Herrera N, Tripolszki K, Beetz C, et al. Combining exome\/genome sequencing with data repository analysis reveals novel gene\u2013disease associations for a wide range of genetic disorders. Genet Med. 2021;23(8):1551\u201368.","journal-title":"Genet Med"},{"issue":"11","key":"2288_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/gim.2013.129","volume":"15","author":"ST South","year":"2013","unstructured":"South ST, Lee C, Lamb AN, Higgins AW, Kearney HM, Working Group for the American College of Medical G, et al. ACMG standards and guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision-2013. Genet Med. 2013;15(11):901\u20139.","journal-title":"Genet Med."},{"issue":"5","key":"2288_CR34","first-page":"405","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet. 2015;17(5):405\u201324.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"2","key":"2288_CR35","first-page":"249","volume":"19","author":"SS Kalia","year":"2017","unstructured":"Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med Off J Am Coll Med Genet. 2017;19(2):249\u201355.","journal-title":"Genet Med Off J Am Coll Med Genet."},{"issue":"D1","key":"2288_CR36","doi-asserted-by":"publisher","first-page":"D1018","DOI":"10.1093\/nar\/gky1105","volume":"47","author":"S Kohler","year":"2019","unstructured":"Kohler S, Carmody L, Vasilevsky N, Jacobsen JOB, Danis D, Gourdine JP, et al. Expansion of the human phenotype ontology (HPO) knowledge base and resources. Nucleic Acids Res. 2019;47(D1):D1018\u201327.","journal-title":"Nucleic Acids Res"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02288-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02288-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02288-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T21:02:29Z","timestamp":1661461349000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02288-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2288"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02288-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project has been conducted within a diagnostic setting, and as a second step, utilized de-identified data and samples. Thus, this did not require Institutional Review Board (IRB) approval in our jurisdiction. Written informed consent was obtained from all patients for genetic studies as well as for the scientific publication of anonymized clinical data and clinical photographs. Additionally, the consent declaration included information regarding the storage of the data and further processing for research purposes. The informed consent form is available in English and several other languages at .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CMR, TW, CB, CP, IS, BDD, GMT, MER, KKK, DS, SM, and PB are current employees, AR is a former employee of Centogene AG. All other authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}